Julia Chudzian

Dr. Julia Chudzian

Protein Engineering, University of Wroclaw, Faculty of Biotechnology, Wrocław, Dolnośląskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Protein Expression and Purification
Verified
Journal Article
Closed access
ASAleksandra Sokolowska-Wedzina
Aleksandra Sokolowska-Wedzina
ABAleksandra Borek
Aleksandra Borek
JCJulia Chudzian
Julia Chudzian
PJPiotr Jakimowicz
Piotr Jakimowicz
MZMalgorzata Zakrzewska
Malgorzata Zakrzewska
JOJacek Otlewski
Jacek Otlewski

1 August 2017 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
ASAleksandra Sokolowska-Wedzina
Aleksandra Sokolowska-Wedzina
GCGrzegorz Chodaczek
Grzegorz Chodaczek
JCJulia Chudzian
Julia Chudzian
ABAleksandra Borek
Aleksandra Borek
MZMalgorzata Zakrzewska
Malgorzata Zakrzewska
JOJacek Otlewski
Jacek Otlewski
Targeted delivery of anticancer drugs using antibodies specific for tumor-associated antigens represents one of the most important approaches in current immuno-oncology research. Fibroblast growth factor receptor 1 (FGFR1) has been demonstrated to be a high-frequency targetable oncogene specific for smoking-associated lung cancers, present in over 20% of lung squamous cell carcinoma cases. This report describes the generation of a potent, fully human antibody fragment in scFv-Fc format efficiently targeting FGFR1. Antibody phage display was used to select high-affinity scFv antibody fragments against the extracellular domain of FGFR1(IIIc). Enzyme immunoassay (ELISA) and surface plasmon resonance (SPR) analysis were used for antibody screening and characterization. The best binder (named D2) was cloned to diabody and Fc fusion formats. All D2 antibodies demonstrated high affinity for FGFR1 with dissociation constants of 18 nmol/L (scFvD2), 0.82 nmol/L (scFvD2 diabody), and 0.59 nmol/L (scFvD2-Fc). scFvD2 was found to be exquisitely selective for FGFR1 versus other FGFR family members and bound FGFR1 even in the presence of its natural ligand FGF2, as shown by competitive analysis. Confocal microscopy revealed that scFvD2-Fc was specifically and rapidly internalized by a panel of cell lines overexpressing FGFR1. Finally, it was demonstrated that scFvD2-Fc mediated specific delivery of a cytotoxic payload into lung cancer cells harboring oncogenic FGFR1 gene amplifications.Implications: This study reports a highly specific internalizing antibody fragment that can serve as a therapeutic targeting agent for efficient delivery of cytotoxic drugs into FGFR1-positive lung cancer cells. Mol Cancer Res; 15(8); 1040–50. ©2017 AACR.

28 November 2024 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
VZVladimira Zlinska
Vladimira Zlinska
ZFZuzana Feketova
Zuzana Feketova
ACAleksandra Czyrek
Aleksandra Czyrek
JCJulia Chudzian
Julia Chudzian
MZMartina Lenarcic Zivkovic
Martina Lenarcic Zivkovic
PKPavel Krejci
Pavel Krejci
Impaired fibroblast growth factor receptor (FGFR) signaling is associated with many human conditions, including growth disorders, degenerative diseases, and cancer. Current FGFR therapeutics are based on chemical inhibitors of FGFR tyrosine kinase activity (TKIs). However, FGFR TKIs are limited in their target specificity as they generally inhibit all FGFRs and other receptor tyrosine kinases. In the search for specific inhibitors of human FGFR1, we identified VZ23, a DNA aptamer that binds to FGFR1b and FGFR1c with a KD of 55 nM and 162 nM, respectively, but not to the other FGFR variants (FGFR2b, FGFR2c, FGFR3b, FGFR3c, FGFR4). In cells, VZ23 inhibited the activation of downstream FGFR1 signaling and FGFR1-mediated regulation of cellular senescence, proliferation, and extracellular matrix homeostasis. Consistent with the specificity toward FGFR1 observed in vitro, VZ23 did not inhibit FGFR2-4 signaling in cells. We show that the VZ23 inhibits FGFR1 signaling in the presence of cognate fibroblast growth factor (FGF) ligands and its inhibitory activity is linked to its capacity to form unusual G-quadruplex structure. Our data suggest that targeting FGFR1 with DNA aptamers could be an effective alternative to TKIs for treating impaired FGFR1 signaling in human craniosynostoses.

14 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
KBKarolina Baran
Karolina Baran
KSKamila Skrzyńska
Kamila Skrzyńska
ACAleksandra Anna Czyrek
Aleksandra Anna Czyrek
AWAdrianna Wiktoria Wittek
Adrianna Wiktoria Wittek
DKDaniel Krowarsch
Daniel Krowarsch
JCJulia Chudzian
Julia Chudzian
Fibroblast growth factors (FGFs) play a key role in lung development by mediating complex interactions between epithelial and mesenchymal cells, which are central to processes such as branching morphogenesis, epithelial differentiation, and alveolarization. The findings regarding this interplay highlight the complexity of FGF signaling, as different FGFs contribute to various aspects of lung formation and maturation. Understanding the role of FGF proteins in shaping the lung is crucial for gaining insight into the biology of its development. Furthermore, FGFs orchestrate complex signaling pathways that regulate lung regeneration in adulthood. Therapeutic strategies targeting FGF-dependent pathways appear promising for repairing and improving lung function in diverse pulmonary diseases. In this review, we describe the current perception of the role of FGF proteins in lung development and regeneration, together with an overview of emerging therapeutic strategies aiming at FGF signaling in lung-related disorders.

Verified
Journal Article
Open access
PDF file
JCJulia Chudzian
Julia Chudzian
ASAnna Szlachcic
Anna Szlachcic
MZMalgorzata Zakrzewska
Malgorzata Zakrzewska
MCMiroslawa Czub
Miroslawa Czub
MPMarcin Pustula
Marcin Pustula
JOJacek Otlewski
Jacek Otlewski
Fibroblast growth factor 1 (FGF1) and its receptors (FGFRs) regulate crucial biological processes such as cell proliferation and differentiation. Aberrant activation of FGFRs by their ligands can promote tumor growth and angiogenesis in many tumor types, including lung or breast cancer. The development of FGF1-targeting molecules with potential implications for the therapy of FGF1-driven tumors is recently being considered a promising approach in the treatment of cancer. In this study we have used phage display selection to find scFv antibody fragments selectively binding FGF1 and preventing it from binding to its receptor. Three identified scFv clones were expressed and characterized with regard to their binding to FGF1 and ability to interfere with FGF1-induced signaling cascades activation. In the next step the scFvs were cloned to scFv-Fc format, as dimeric Fc fusions prove beneficial in prospective therapeutic application. As expected, scFvs-Fc exhibited significantly increased affinity towards FGF1. We observed strong antiproliferative activity of the scFvs and scFvs-Fc in the in vitro cell models. Presented antibody fragments serve as novel FGF1 inhibitors and can be further utilized as powerful tools to use in the studies on the selective cancer therapy.

15 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KJKarolina Jendryczko
Karolina Jendryczko
JCJulia Chudzian
Julia Chudzian
NSNatalia Skinder
Natalia Skinder
ŁOŁukasz Opaliński
Łukasz Opaliński
JRJakub Rzeszótko
Jakub Rzeszótko
ASAnna Szlachcic
Anna Szlachcic
Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a selective targeting agent and drug carrier. Short peptide based on FGF2 sequence was used to construct a FGFR1-targeting peptibody. We have shown that this peptide ensures specific delivery of peptibodyF2 into FGFR1-expressing cells. In order to use peptibodyF2 as a delivery vehicle for cytotoxic drugs, we have conjugated it with MMAE, a drug widely used in antibody–drug conjugates for targeted therapy. Resulting conjugate shows high and specific cytotoxicity towards FGFR1-positive cells, i.e., squamous cell lung carcinoma NCI-H520, while remaining non-toxic for FGFR1-negative cells. Such peptibody–drug conjugate can serve as a basis for development of therapy for tumors with overexpressed or malfunctioning FGFRs.